PBMWW
Psyence Biomedical Ltd.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.024
- Prev close
- 0.012
- Mkt cap
- 855
- Vol
- 33.88K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0117
- High
- 0.0121
- Forward P/E
- 0.00
- Beta
- -0.42
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- -0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.71M
- Total cash
- 733.19K
- Total debt
- 7.66M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- psyencebiomed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PBMWW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 9.34% | 1,220,986 | 23.20K | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 5.61% | 733,000 | 13.93K | Sep 29, 2024 |
| MMCAP International, Inc. SPC | 4.59% | 600,000 | 11.40K | Sep 29, 2024 |
| Calamos Advisors LLC | 3.83% | 500,000 | 9.50K | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 3.58% | 468,500 | 8.90K | Sep 29, 2024 |
| Saba Capital Management, L.P. | 2.28% | 297,847 | 5.66K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Calamos Market Neutral Income Fund | 3.83% | 500,000 | 9.50K | Oct 30, 2024 |
| Merger Fund, The | 0.65% | 85,245 | 1.62K | Sep 29, 2024 |
| Saba Capital Income & Opportunities Fd | 0.23% | 30,398 | 577 | Jul 30, 2024 |
| JNL Series Trust-JNL/Multi Manager Alternative Fund | 0.03% | 4,024 | 76 | Sep 29, 2024 |
| Principal Global Multi Strategy Fd | 0.01% | 974 | 18 | Aug 30, 2024 |
| WCM Alternatives Credit Event Fund | 0.01% | 733 | 13 | Sep 29, 2024 |